Healthcare Sector Head @Hedgeye
Cite asCryptoQuant has tracked the directional calls on NVO by @HedgeyeHC on X since Jul 2013: not yet scored on NVO (as of Nov 11, 2026).
4 NVO calls on record, a thin history.
Relative view by default: fewer than 30 NVO calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @HedgeyeHC to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
Medicare Bridge program is gaining momentum into its July 1 launch; $50/month weight loss drugs could broaden GLP-1 access and volumes for LLY and NVO
$LLY $NVO #GLP1 $XLV Medicare Bridge program gathering momentum into July 1 launch. Weight loss drugs for $50 a month likely transforms healthcare. https://t.co/hl86AUO76V
View original →$NVO long presentation starting shortly... Already working on the deck for next week where we'll walk through the impact to medical utilization if GLP-1 adoption ramps as we expect. More reasons to not like $HCA and $THC. @HedgeyeHealth @Hedgeye
View original →Spent more time scoring $XLV constituents for AI sensitivity and recent performance making much more sense. $TXG still looks like a marginal winner even if $XBI under pressure. $RDNT benefits in similar ways to $HCA. $HIMS goes away, $NVO (and pharma) long term winner.
View original →$NVO oral GLP-1 launch is on a tear, lowering BMI lowers medical costs, the weight loss might be permanent (below). Lots to do if this starts showing up in utilization data… https://t.co/UfjNX7Tu2f
View original →@claudiothesame I didn’t really have $NVO thoughts to change. A cheap oral GLP-1 might have a real return in health cost savings. Might even be break even on food costs for the patient. $LFMD apps makes it easy from what I found and app downloads picking up…
View original →
